Virginia is currently home to 1856 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The HOPE Study: Characterizing Patients With Hepatitis B and C
Recruiting
This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and evaluation of disease progression. In addition, there is a longitudinal sub-study for treatment of hepatitis B that will involve 2 years of treatment with tenofovir alafenamide and blood collections w... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/13/2025
Locations: Dr Huong Dang, Medical Practice, Falls Church, Virginia
Conditions: Hepatitis B, Chronic, Hepatitis C
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Recruiting
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary anti-tumor activity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Advanced Solid Tumors
Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study
Recruiting
Statins are a class of cholesterol lowering medications that contribute to reducing a person's risk of experiencing a cardiovascular event like heart attack. Along with the ability to lower cholesterol, statins also possess anti-inflammatory properties which contribute to their cardioprotective effects. Some people experience side effects while taking statins and are unable to continue treatment with them,which can then increase a person's risk of having cardiovascular issues due to untreated hi... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Statin Adverse Reaction
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Recruiting
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
Recruiting
A randomized crossover trial assessing glycemic control using Reinforcement Learning trained Bolus Priming System (BPS_RL) added to the the Automated Insulin Delivery as Adaptive NETwork (AIDANET algorithm) compared to the original AIDANET algorithm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Virginia Center for Diabetes Technology, Charlottesville, Virginia
Conditions: Type 1 Diabetes
Improving Traumatic Brain Injury Rehab Care With Comm Health Services: a Research Project Within the TBI Model System
Recruiting
TBI rehabilitation care transitions refer to the processes of preparing patients, families, and community-based healthcare providers for the patient's passage from inpatient rehabilitation to the home and community or to another level of care. Persons with TBI have heterogenous neurological impairment (cognitive and behavioral foremost, along with motor, sensory, and balance), that limits their functional independence and participation, and increases their risk for secondary medical conditions,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Traumatic Brain Injury
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
Recruiting
This study is being done to compare the effectiveness of de novo Letermovir versus valganciclovir in preventing the development of cytomegalovirus viremia or symptomatic disease in African American kidney transplant recipients within the first year after transplantation. There are two arms in the study: Arm 1: Prophylaxis: This group includes freshly transplanted high risk (CMV D+/R-) African American Kidney recipients who will be on prophylactic Letermovir for 6 month. Arm 2: Prophylaxis: Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: VCU Medical Center, Richmond, Virginia
Conditions: Kidney Transplant; Complications, CMV
Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes
Recruiting
The purpose of this research study is to evaluate a transition preparation program designed for adolescents and young adults (AYAs) with type 1 diabetes (T1D). This transition program will support AYAs as they prepare to transition from pediatric to adult endocrinology medical care and will also include a caregiver. Results from this study will inform clinical recommendations regarding self-management best practices for AYAs with T1D prior to transitioning to adult medical care.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Type 1 Diabetes
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Recruiting
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Sentara Norfolk General Heart Hospital, Norfolk, Virginia
Conditions: Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Recruiting
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Augusta Health Center for Cancer and Blood Disorders, Fishersville, Virginia
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Local Institution - 017-814-A, Arlington, Virginia
Conditions: Advanced NSCLC, Metastatic Lung Cancer